Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

AGM Statement

6 Sep 2023 07:00

RNS Number : 4715L
Omega Diagnostics Group PLC
06 September 2023
 

Omega Diagnostics Group plc

('Omega' or the 'Company')

 

AGM Statement

 

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health and Nutrition products, will hold its Annual General Meeting (AGM) today at 11.00am at Poets House, St Mary's Street, Ely, CB7 4EY.

 

Ahead of the meeting, Simon Douglas, Chairman of the Company, will make the following statement:

 

"At the start of the new financial year we continue to work towards achieving our strategic objectives for our Health and Nutrition Business, maintaining our market leading position whilst targeting organic growth to gain momentum and create value for our shareholders.

 

Whilst we maintain a very strong order book, one of our leading products, the FoodPrint® test, had some production challenges towards the end of the year which resulted in a drop in production yields and, as a consequence, a backlog in the fulfilment of some orders. As announced with our results last month, we have embedded new working practices that are now generating significantly higher production yields that will allow us to successfully address the order backlog. We have established new preventative procedures and will continue to make further improvements. 

 

We remain well-funded to deliver against our strategic objectives. We have started our journey into the US market and we will continue to work closely with strategic partners to develop bespoke microbiome and nutrigenomic test reports. The recent successful launch of our new digital "app", MyHealthTracker, will support our strong position in the market and give us a direct connection with our customers.

 

We are implementing the final parts of the turnaround strategy outlined last year. A turnaround year where we established a clear focus, with new objectives. It has seen a significant shift in the business, and our proposed name change to Cambridge Nutritional Sciences PLC (LON: CNSL) builds on our CNSLab brand and better reflects our goal of promoting a personalised and functional approach to health and nutrition. We will continue to reshape and restructure the Company as we implement our new strategy.

 

Finally, as previously announced, the Board continues to vigorously pursue its substantial counterclaim for losses incurred towards the DHSC, as a direct result of its failure to licence the necessary intellectual property to permit the contract to move forward and their failure to notify the Group of their inability to do so in a timely manner.

 

We as a Board remain positive and believe we are well-positioned to re-focus the business and build an exciting profitable enterprise for everyone and look forward to updating our shareholders in November at the Company's half year results."

 

Contacts: 

 

Omega Diagnostics Group PLC

www.omegadx.com

Jag Grewal, Chief Executive Officer

via Walbrook PR

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash / Edward Whiley / George Dollemore (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus / Lianne Applegarth

Mob: 07980 541 893 / 07584 391 303

Sam Allen

Mob: 07502 558 258

 

 

About Omega Diagnostics Group PLC

Omega (AIM: ODX) is a specialist medical diagnostics company focused on industry-leading Health and Nutrition products.

 

www.omegadx.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMSSEFMIEDSEEU
Date   Source Headline
2nd Mar 20217:00 amRNSContract with Screen4
24th Feb 20217:00 amRNSUK-RTC statement on AbC-19TM rapid antibody test
19th Feb 20211:45 pmRNSDirector/PDMR Shareholding
18th Feb 202110:00 amRNSDirector/PDMR Shareholding
16th Feb 20217:00 amRNSAbC-19TM rapid antibody test performance data
15th Feb 20217:00 amRNSDirector/PDMR Shareholding
11th Feb 20219:00 amRNSPrice Monitoring Extension
11th Feb 20217:01 amRNSUK Government contract and trading update
11th Feb 20217:00 amRNSDirectorate Change
8th Feb 20219:05 amRNSSecond Price Monitoring Extn
8th Feb 20219:00 amRNSPrice Monitoring Extension
8th Feb 20217:00 amRNSStatement re Media Comment
2nd Feb 20218:45 amRNSExercise of Options and Total Voting Rights
28th Jan 20211:15 pmRNSExercise of Options and Total Voting Rights
27th Jan 20214:41 pmRNSSecond Price Monitoring Extn
27th Jan 20214:35 pmRNSPrice Monitoring Extension
26th Jan 20217:02 amRNSLab-based COVID-19 antibody test service launch
26th Jan 20217:01 amRNSUpdate re AbC-19 Rapid Test
25th Jan 202111:06 amRNSSecond Price Monitoring Extn
25th Jan 202111:00 amRNSPrice Monitoring Extension
22nd Jan 202110:15 amRNSExercise of Options and Total Voting Rights
22nd Jan 20219:05 amRNSSecond Price Monitoring Extn
22nd Jan 20219:00 amRNSPrice Monitoring Extension
11th Jan 202111:00 amRNSExercise of Options and Total Voting Rights
29th Dec 20207:01 amRNSUpdate re AbC-19 Rapid Test
29th Dec 20207:00 amRNSAbC-19TM Rapid Test Update
24th Dec 202012:41 pmRNSSecond Price Monitoring Extn
24th Dec 202012:35 pmRNSPrice Monitoring Extension
24th Dec 202012:00 pmRNSMologic CE Mark Rapid Antigen Test
24th Dec 202011:05 amRNSSecond Price Monitoring Extn
24th Dec 202011:00 amRNSPrice Monitoring Extension
11th Dec 20202:05 pmRNSSecond Price Monitoring Extn
11th Dec 20202:00 pmRNSPrice Monitoring Extension
11th Dec 20209:45 amRNSExercise of Options and Total Voting Rights
7th Dec 20208:00 amRNSExercise of Options and Total Voting Rights
2nd Dec 20209:00 amRNSDirector/PDMR Shareholding
30th Nov 20202:30 pmRNSExercise of Options and Total Voting Rights
30th Nov 20207:00 amRNSInterim Results
25th Nov 20202:06 pmRNSSecond Price Monitoring Extn
25th Nov 20202:01 pmRNSPrice Monitoring Extension
23rd Nov 20209:45 amRNSExercise of Options and Total Voting Rights
17th Nov 20207:45 amRNSUK-RTC Update
16th Nov 20207:16 amRNSHolding(s) in Company
16th Nov 20207:15 amRNSHolding(s) in Company
13th Nov 20202:05 pmRNSSecond Price Monitoring Extn
13th Nov 20202:00 pmRNSPrice Monitoring Extension
13th Nov 20209:30 amRNSExercise of Options and Total Voting Rights
12th Nov 20203:42 pmRNSUK-RTC Statement
12th Nov 202011:05 amRNSSecond Price Monitoring Extn
12th Nov 202011:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.